agenus inc (AGEN) Key Developments
Agenus Seeks Acquisitions
May 20 15
Agenus Inc. (NasdaqCM:AGEN) is looking for acquisitions. The company has filed a Follow-on Equity Offering and intends to use the net proceeds from this offering to fund our continued research and development initiatives in connection with expanding our product pipeline and for other general corporate purposes, which may include working capital, capital expenditures, and clinical trial expenditures, acquisitions of additional companies or technologies and investments.
Agenus Inc. - Shareholder/Analyst Call
May 8 15
To provide an overview of the company’s proprietary and partnered pipeline, including its antibody platforms and checkpoint modulator programs, its heat shock protein-based vaccine platform and its saponin-based vaccine adjuvant platform and to provide update on its strategic alliances, including those with Incyte and Merck, and its recent strategic acquisition, all within the framework of its overall corporate strategy
Agenus Inc. Announces the Final Results from the Phase 3 Study of Glaxosmithkline’s Malaria Vaccine
Apr 24 15
Agenus Inc. announced that final results from a large-scale Phase 3 study of GlaxoSmithKline’s malaria vaccine candidate. The study demonstrated a statistically significant reduction against malaria in children who received RTS,S followed by a booster shot of the vaccine at 18 months. RTS,S reduced the number of cases of clinical malaria in young children (aged 5-17 months at first vaccination) by 36%, and in infants (aged 6-12 weeks) by 26% over an average follow-up period of 48 months. This resulted in an average reduction of 1,774 cases of clinical malaria for every 1,000 children vaccinated (aged 5-17 months), and an average reduction of 983 cases of clinical malaria for every 1,000 infants vaccinated over an average 36-month follow-up. Children receiving the vaccine candidate but not a booster dose had lower rates of protection. The study showed that RTS,S averted even more cases of malaria in areas with higher transmission rates. Agenus is eligible for a milestone payment upon approval of RTS,S and royalties from potential commercial sales. QS-21 Stimulon is being evaluated in more than 12 additional vaccine candidates.
Agenus Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015
Apr 23 15
Agenus Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of $3,953,000 compared to $721,000 a year ago. Operating loss was $18,292,000 compared to $9,824,000 a year ago. Net loss attributable to common stockholders of $18,793,000, or $0.28 per share, basic and diluted, compared with a net loss attributable to common stockholders for the first quarter of 2014 of $408,000, or $0.01 per share, basic and diluted. The increase in net loss attributable to common stockholders for the quarter ended March 31, 2015, compared to the net loss attributable to common stockholders for the same period in 2014, was primarily due to non-cash, fair value adjustments of contingent liabilities in 2015 and non-cash, non-operating income during the quarter ended March 31, 2014. The company’s cash burn (cash provided by operating activities excluding up-front fees received and contingent purchase price payments) for the first quarter of 2015 was $10.7 million compared to $10.1 million for the same period in 2014.
Agenus Inc. to Report Q1, 2015 Results on Apr 23, 2015
Apr 20 15
Agenus Inc. announced that they will report Q1, 2015 results at 9:00 AM, Eastern Standard Time on Apr 23, 2015